Ondine Biomedical (OBI) Competitors

Ondine Biomedical has higher earnings, but lower revenue than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Ondine Biomedical, indicating that it is currently the more affordable of the two stocks.

Oxford Nanopore Technologies has a consensus price target of GBX 198.60, suggesting a potential downside of 7.69%. Given Oxford Nanopore Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Oxford Nanopore Technologies is more favorable than Ondine Biomedical.

Ondine Biomedical has a beta of 0.298, meaning that its share price is 70% less volatile than the broader market. Comparatively, Oxford Nanopore Technologies has a beta of 0.871, meaning that its share price is 13% less volatile than the broader market.

32.8% of Ondine Biomedical shares are owned by institutional investors. Comparatively, 18.3% of Oxford Nanopore Technologies shares are owned by institutional investors. 29.0% of Ondine Biomedical shares are owned by insiders. Comparatively, 2.5% of Oxford Nanopore Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Oxford Nanopore Technologies has a net margin of -54.66% compared to Ondine Biomedical's net margin of -1,150.26%. Oxford Nanopore Technologies' return on equity of -35.45% beat Ondine Biomedical's return on equity.

In the previous week, Oxford Nanopore Technologies had 7 more articles in the media than Ondine Biomedical. MarketBeat recorded 7 mentions for Oxford Nanopore Technologies and 0 mentions for Ondine Biomedical. Oxford Nanopore Technologies' average media sentiment score of 0.77 beat Ondine Biomedical's score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the news media.

32.8% of Ondine Biomedical shares are owned by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are owned by institutional investors. 29.0% of Ondine Biomedical shares are owned by insiders. Comparatively, 25.8% of Oxford Biomedica shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Ondine Biomedical has higher earnings, but lower revenue than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Ondine Biomedical, indicating that it is currently the more affordable of the two stocks.

Oxford Biomedica has a consensus price target of GBX 613.32, indicating a potential upside of 19.32%. Given Oxford Biomedica's stronger consensus rating and higher possible upside, analysts clearly believe Oxford Biomedica is more favorable than Ondine Biomedical.

Oxford Biomedica has a net margin of -23.23% compared to Ondine Biomedical's net margin of -1,150.26%. Oxford Biomedica's return on equity of -54.51% beat Ondine Biomedical's return on equity.

In the previous week, Oxford Biomedica had 1 more articles in the media than Ondine Biomedical. MarketBeat recorded 1 mentions for Oxford Biomedica and 0 mentions for Ondine Biomedical. Ondine Biomedical's average media sentiment score of 0.00 equaled Oxford Biomedica'saverage media sentiment score.

Ondine Biomedical has a beta of 0.298, meaning that its share price is 70% less volatile than the broader market. Comparatively, Oxford Biomedica has a beta of 1.106, meaning that its share price is 11% more volatile than the broader market.

Silence Therapeutics has higher revenue and earnings than Ondine Biomedical. Ondine Biomedical is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Silence Therapeutics has a net margin of 0.00% compared to Ondine Biomedical's net margin of -1,150.26%. Silence Therapeutics' return on equity of 0.00% beat Ondine Biomedical's return on equity.

In the previous week, Silence Therapeutics' average media sentiment score of 0.00 equaled Ondine Biomedical'saverage media sentiment score.

32.8% of Ondine Biomedical shares are owned by institutional investors. 29.0% of Ondine Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Ondine Biomedical has a net margin of -1,150.26% compared to Avacta Group's net margin of -35,730.97%. Avacta Group's return on equity of -1,293.07% beat Ondine Biomedical's return on equity.

In the previous week, Avacta Group had 1 more articles in the media than Ondine Biomedical. MarketBeat recorded 1 mentions for Avacta Group and 0 mentions for Ondine Biomedical. Avacta Group's average media sentiment score of 0.00 equaled Ondine Biomedical'saverage media sentiment score.

Ondine Biomedical has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Ondine Biomedical, indicating that it is currently the more affordable of the two stocks.

2.9% of Avacta Group shares are held by institutional investors. Comparatively, 32.8% of Ondine Biomedical shares are held by institutional investors. 47.7% of Avacta Group shares are held by insiders. Comparatively, 29.0% of Ondine Biomedical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Avacta Group has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, Ondine Biomedical has a beta of 0.298, suggesting that its stock price is 70% less volatile than the broader market.